A South Dakota overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
South Dakota's adult obesity rate has climbed to 37.0% as of 2024, up from 33.2% in 2020 — a nearly four-point rise in four years that puts the state among the higher-obesity states nationally 1.
South Dakota Medicaid sits in the most restrictive tier KFF tracks: no GLP-1 coverage for weight loss, and no other anti-obesity drug either 34.
No. South Dakota Medicaid does not cover GLP-1 medications — or any other anti-obesity drug — for weight-loss treatment, as of October 1, 2025, per the KFF/HMA 50-State Medicaid Budget Survey FY 2025-2026 34. That is the most restrictive of the three tiers KFF tracks: nationally, 16 states cover GLP-1s for obesity and 22 cover some anti-obesity drug, and South Dakota is in neither group 3. Neighboring North Dakota sits in the middle tier, with an anti-obesity drug benefit that still excludes GLP-1s 3.
South Dakota Medicaid does already cover GLP-1s where federal rules make coverage mandatory: diabetes, and, since 2024, cardiovascular disease and moderate-to-severe obstructive sleep apnea 3. The obesity indication specifically is the gap. The state's PDL and prior-authorization criteria are administered by OptumRx 5; the underlying PDL application could not be read directly this pass, so the KFF/HMA survey is the dated, authoritative proxy cited here rather than a primary PDL document.
Eligibility is tightening at the same time. South Dakota has ACA Medicaid Expansion in place, but the federal H.R.1 reconciliation law signed July 4, 2025 adds new community-engagement and work requirements and 6-month renewals for expansion enrollees starting January 1, 2027, and cost-sharing above 100% of the federal poverty line starting October 1, 2028 6. Eligibility is getting harder for this group at the same time there is no obesity-drug benefit to lose.
Astra's price in South Dakota is the price everywhere else we operate: $68 a month for compounded semaglutide and $118 a month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416, the same at every dose. There is no South Dakota price list, no regional surcharge, and no local discount.
8.1% of South Dakotans are uninsured and median household income is $76,881, per the Census Bureau's ACS 2024 1-year estimates 7. Both figures are 1-year estimates, which carry a wider margin of error at the state level than a 5-year estimate would — reliable for context, not for tight statistical claims 7.
South Dakota's telehealth prescribing rules for GLP-1 medications are still being confirmed. Check back for board-specific guidance. We are not naming a board or linking one until the operative authority and current practice-act language are sourced.
Astra is licensed to treat patients in all 50 states, including South Dakota — Sioux Falls, Rapid City, and every rural county alike. Care starts online; there's no in-state clinic visit required, and the price doesn't change based on where in South Dakota a patient lives.
Astra treats patients in South Dakota through state-licensed physicians.
Sioux Falls, the state's largest city, has its own page for city-level data and local access.
No. As of October 1, 2025, South Dakota Medicaid does not cover GLP-1 medications for obesity treatment under fee-for-service — one of 29 states in this category, per KFF's 2025 survey of state Medicaid officials. South Dakota Medicaid does cover GLP-1s when prescribed for diabetes, and since 2024, for cardiovascular disease or moderate-to-severe sleep apnea, but not for weight loss on its own.
No — and that's true everywhere. Astra charges the same national price in every state: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416/year). There's no South Dakota markup and no regional discount; the price for a Sioux Falls address is the same one a patient in any other state sees.
Yes. Astra is licensed in all 50 states, so South Dakota residents anywhere in the state — not just Sioux Falls — can start care online without traveling to an in-person clinic.
The state's adult obesity prevalence rose from 33.2% in 2020 to 37.0% in 2024 (CDC BRFSS). The CDC dataset tracks the trend but doesn't isolate a single cause; the pattern mirrors a broader rise across much of the country over the same period.
No referral is required to see an Astra provider. Prior authorization is a Medicaid/insurance-specific process tied to a plan's own drug list (South Dakota Medicaid's is administered by OptumRx); Astra's cash-pay model doesn't run through that process, so it doesn't apply to an Astra prescription.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.